By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Alkylating agents > Carboplatin > Carboplatin Dosage
Alkylating agents
https://themeditary.com/dosage-information/carboplatin-dosage-10982.html

Carboplatin Dosage

Drug Detail:Carboplatin (Carboplatin [ kar-boe-pla-tin ])

Drug Class: Alkylating agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Ovarian Cancer

SINGLE AGENT THERAPY for use in the treatment of recurrent ovarian cancer:
360 mg/m2 by IV on day 1 every 4 weeks (alternatively, the carboplatin dose may be calculated by the Calvert formula below). Usually, single intermittent courses should not be repeated until the neutrophil count is at least 2000 and the platelet count is at least 100,000.

COMBINATION THERAPY (with cyclophosphamide) for use in the treatment of advanced ovarian cancer (an effective combination for previously untreated patients):

  • Carboplatin: 300 mg/m2 by IV on day 1 every 4 weeks for 6 cycles (alternatively, the carboplatin dose may be calculated by the Calvert formula below)
  • Cyclophosphamide 600 mg/m2 IV on day 1 every 4 weeks for 6 cycles
  • Intermittent courses of carboplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2000 and the platelet count is at least 100,000.

FORMULA DOSING: Another way to determine the initial dose is the use of a mathematical formula based on a patient's preexisting renal function or renal function and desired platelet nadir (renal excretion is the major route of elimination for this drug). The use of this formula allows compensation for patient variations in pretreatment renal function that might otherwise result in either under dosing (in patients with above average renal function) or overdosing (in patients with impaired renal function).
  • CALVERT FORMULA: Total Dose (mg) = (target AUC) x (GFR + 25); Note: With the Calvert formula, the total dose of carboplatin is calculated in mg, not mg/m2

Comments:
  • This drug is usually administered by an infusion lasting 15 minutes or longer.
  • No pre- or post-treatment hydration or forced diuresis is required.
  • The target AUC of 4 to 6 mg/mL/min using single agent carboplatin appears to provide the most appropriate dose range in previously treated patients.
  • To avoid potential toxicity due to overdosing, if a patient's GFR is estimated based on serum creatinine measured by the standardized Isotope Dilution Mass Spectrometry (IDMS) method rather than using an actual GFR measurement, a capping of the dose of carboplatin for the desired exposure (AUC) has been recommended.

Uses:
  • For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide.
  • For the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.

Renal Dose Adjustments

Patients with Impaired Kidney Function:
Patients with creatinine clearance values below 60 mL/min are at increased risk of severe bone marrow suppression. In renally-impaired patients who received single agent carboplatin therapy, the incidence of severe leukopenia, neutropenia, or thrombocytopenia has been about 25% when the dosage modifications in the table below have been used.

  • CrCl 41 to 59 mL/min: The recommended dose on Day 1 is 250 mg/m2
  • CrCl 16 to 40 mL/min: The recommended dose on Day 1 is 200 mg/m2
  • CrCl less than 15 mL/min: Data not available

These dosing recommendations apply to the initial course of therapy; adjust subsequent doses according to patient tolerance based on the degree of bone marrow suppression.

Liver Dose Adjustments

Data not available

Dose Adjustments

Pretreatment platelet count and performance status are important prognostic factors for severity of myelosuppression in previously treated patients. The suggested dose adjustments for single agent or combination therapy shown below are modified from controlled trials in previously treated and untreated patients with ovarian carcinoma. Blood counts were done weekly, and the recommendations are based on the lowest posttreatment platelet or neutrophil value:

  • Platelets greater than 100,000 and neutrophils greater than 2000: Adjust dose from prior course to 125%
  • Platelets 50,000 to 100,000 and neutrophils 500 to 2000: No adjustment
  • Platelets less than 50,000: adjust dose from prior course to 75%
NOTE: Percentages apply to carboplatin as a single agent or to both carboplatin and cyclophosphamide in combination. In studies dosages were also adjusted at a lower level (50% to 60%) for severe myelosuppression. Escalations above 125% were not recommended.

Precautions

US BOXED WARNINGS:

  • This drug should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents in an adequate treatment facility.
  • Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding.
  • Anemia may be cumulative and may require transfusion support.
  • Vomiting is a frequent side effect.
  • Anaphylactic reactions to this drug have been reported and may occur within minutes of administration; epinephrine, corticosteroids, and antihistamines alleviate symptoms.

CONTRAINDICATIONS:
  • Hypersensitivity to the active component, any of the ingredients, or platinum-containing compounds
  • Additional and/or more frequent monitoring should be done to ensure receipt of an effective dose while avoiding unnecessary toxicities
  • Severe bone marrow depression
  • Severe bleeding

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Storage requirements:

  • Store unopened vials at 25C (77F); excursions permitted from 15 to 30C (59 to 86F). Protect from light.

Reconstitution/preparation techniques:
  • Injection multi-dose vials maintain microbial, chemical, and physical stability for up to 14 days at 25C following multiple needle entries.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
  • Solutions for infusion should be discarded 8 hours after preparation.

IV compatibility:
  • The manufacturer product information should be consulted.

General:
  • To minimize the risk of dermal exposure, wear impervious gloves when handling vials.
  • If this drug contacts the skin, immediately wash thoroughly with soap and water. -If this drug contacts mucous membranes, the membranes should be flushed immediately and thoroughly with water.
  • Aluminum reacts with carboplatin injection causing precipitate formation and loss of potency; therefore, needles or IV sets containing aluminum parts that may come in contact with the drug should not be used for preparation or administration.

Frequently asked questions

  • Why give Taxol (Paxel) before carboplatin?
  • Does carboplatin cause neuropathy?
  • How does carboplatin stop cancer?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by